Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

Completed · Phase 2 · Has a placebo group

Conditions studied: Patients Who Participated in an Intravitreal Brimo PS DDS® Study

In brief

This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

Key facts

Study ID

NCT01080209

Run by

Allergan

People needed

215

Starts

2010-02-01

Expected to finish

2014-02-01

Last updated by the study team

2015-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason
• Applicable studies: Previous Allergan intravitreal Brimo PS DDS® treatment studies

You may not qualify if…

• None

Where it is running

• Study site — Artesia, California, United States
• Study site — Sydney, New South Wales, Australia
• Study site — Westmead, New South Wales, Australia
• Study site — Brno, Czechia
• Study site — Paris, France
• Study site — Karlsruhe, Germany
• Study site — New Delhi, New Delhi, India
• Study site — Tel Aviv, Israel
• Study site — Udine, Italy
• Study site — Makati, Philippines
• Study site — Coimbra, Portugal
• Study site — Seoul, South Korea
• Study site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.